Nextgen Bioscience Co. Ltd. has divulged ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of cancer, fibrosis, cardiovascular, inflammatory, respiratory, metabolic, eye and renal disorders, among others.<
Ohio State University has synthesized DNA topoisomerase II (bacterial) inhibitors reported to be useful for the treatment of Staphylococcus aureus infections.
Nanjing Tian Yin Jian Hua Pharma Tech Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors acting as necroptosis inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, ulcerative colitis, multiple sclerosis, psoriasis, rheumatoid arthritis and Alzheimer’s disease, among others.
Precision Biosciences Inc. has received pre-IND regulatory feedback from the FDA and ex-U.S. agencies providing alignment and clarity on Precision's final IND/CTA-enabling preclinical plans and clinical strategy for PBGENE-HBV.
Vantai Inc. and Bristol Myers Squibb Co. have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.
Investigators from the Chinese Academy of Medical Sciences & Peking Union Medical College presented data from a study that investigated the regulatory mechanisms of intestinal epithelial cell (IEC) death and intestinal inflammation.
RSS
